Blog

Welcome to our blog! This is where we share a bit more – insights, updates, and thoughts from Genovis. Take a look around and see what you find.

FabRICATOR® Xtra LALA for Ultrafast Microdroplet Digestion of Antibodies with Fc-silencing Mutations
2025-06-13
Scientists at New Jersey Institute of Technology, Johnson & Johnson and collaborators have demonstrated a novel approach for mass spectrometry (MS)-based characterization of hinge-mutated antibodies. Combining the recently introduced FabRICATOR Xtra LALA enzyme with ultrafast microdroplet digestion allows for fully automated, high-throughput and efficient antibody characterization, with the entire sample preparation and MS analysis completed…
Evaluating the Impact of Antibody Fragments on Aggregation using FabALACTICA®
2025-04-01
Scientists at Biogen have developed an approach to better understand monoclonal antibody (mAb) aggregation by characterizing fragments that may form during the production process. Fab/c fragments – common impurities generated through hinge digestion and loss of a Fab subunit – can offer valuable insights into aggregation mechanisms. To support this work, FabALACTICA, which specifically digests…
Multi-Attribute mAb Variant Characterization with CE-MS and FabRICATOR® Digestion
2025-02-20
Scientists at Aalen University and their collaborator present a detailed methodology for the rapid and thorough characterization of monoclonal antibody (mAb) variants using capillary electrophoresis-mass spectrometry (CE-MS) at the subunit level. mAbs are an important class of therapeutic molecules for treating various diseases, including cancer and autoimmune disorders. mAbs are large, complex molecules and can…
GlyCLICK®-generated ADC Suppresses Tumor Growth in Pancreatic Cancer Models
2025-01-24
Scientists at The Finsen Laboratory and collaborators have described the potential for a novel antibody-drug conjugate (ADC) to treat pancreatic ductal adenocarcinoma (PDAC). The ADC candidate is conjugated with a highly potent anthracycline payload (PNU-159682) using GlyCLICK conjugation technology, and targets uPAR (urokinase plasminogen activator receptor), a protein overexpressed in PDAC and its surrounding stroma.…
From Nobel Discoveries to New Frontiers in RNA Integrity
2024-12-09
On this Nobel Day, we honor two monumental breakthroughs in RNA research recognized by the Nobel Prize in Physiology or Medicine! 🏆
[GenovisWebinar!] 🤩 Unlocking Antibody Insights with Regeneron: SmartEnzymes™ in Action!
2024-11-26
We are thrilled to welcome Xin Wang from Regeneron Pharmaceuticals to showcase how the reliability and robust performance of Genovis’ SmartEnzymes have enabled their subunit HILIC-MS method to be successfully applied across multiple Regeneron programs and commercial mAbs.
[New Launch] SEQURNA™ RNase Inhibitor Thermostable
2024-11-14
We’re excited and proud to launch a new solution for securing RNA integrity! SEQURNA RNase Inhibitor Thermostable is a fully synthetic and heat-tolerant inhibitor that protects RNA integrity. It is active across a wide temperature range, providing sustainability through ambient storage and shipping, minimizes batch effects, and avoids activity loss from freeze-thaw cycles and…
SEQURNA™ Brings Synthetic RNase Inhibitors to Single-Cell Transcriptomics!
2024-10-21
Scientists at the Karolinska Institute have demonstrated the construction of single-cell RNA sequencing (scRNA-seq) libraries using SEQURNA RNase Inhibitor Thermostable, a novel, fully synthetic, and thermostable RNase inhibitor. SEQURNA overcomes the limitations of traditional recombinant RNase inhibitors (RRIs) by providing superior thermal stability, enhanced reproducibility, and logistical convenience. Its use enabled the creation of high-quality…
NEW! We’re Launching FabRICATOR Xtra LALA Lyophilized!
2024-09-19
We're excited to share that we are launching a new member of the SmartEnzymes™ family that will facilitate middle-level analysis of hinge-mutated IgG! FabRICATOR Xtra LALA is an IgG-specific protease that digests antibodies which have been engineered to contain mutated hinges, including the LALA mutation. It digests below the hinge, generating F(ab’)2 and Fc…
IgMBRAZOR™ in a Study on Structural Characterization of IgM
2024-06-19
Scientists at Utrecht University and collaborators have described the use of online SEC combined with Orbitrap-based CDMS to perform real-time kinetic monitoring of pentameric IgM digestion by the protease IgMBRAZOR, a novel protease which digests specifically at a single site in the hinge region of IgM. While IgMBRAZOR was shown to efficiently digest IgM, it…
NEW! We’re Launching TransGLYCIT™ Remodeling Afucosylated Man5!
2024-05-06
We are proudly launching a new format of our popular TransGLYCIT technology! With TransGLYCIT Remodeling Afucosylated Man5, it is possible to generate human IgG with fully homogenous Man5 glycoforms within a few hours! TransGLYCIT is a platform technology that enables efficient and site-specific human IgG glycan remodeling or conjugation. With TransGLYCIT, antibodies with defined and…
TransGLYCIT™ in a Study on Antibody Characterization
2024-04-30
Scientists from the Wistar Institute in Philadelphia and collaborators have studied the IgG N-glycan structures and inflammatory aging markers of people living with and without HIV to determine a potential structure-function relationship. In this study, TransGLYCIT was used to generate anti-HIV antibodies with defined N-glycan structures to study Fc-mediated immune activities in vitro.